2024년에 9억 1,350만 달러로 추정되는 세계의 오믹스 연구용 인공지능 시장은 2024-2030년에 CAGR 30.4%로 성장하며, 2030년에는 45억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 AI 소프트웨어는 CAGR 27.7%를 기록하며, 분석 기간 종료시에는 27억 달러에 달할 것으로 예측됩니다. AI 서비스 분야의 성장률은 분석 기간에 CAGR 35.3%로 추정됩니다.
미국 시장은 2억 4,010만 달러로 추정, 중국은 CAGR 28.9%로 성장 예측
미국의 오믹스 연구용 인공지능 시장은 2024년에 2억 4,010만 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 분석 기간인 2024-2030년의 CAGR을 28.9%로 2030년까지 6억 7,970만 달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 27.3%와 26.5%로 예측됩니다. 유럽에서는 독일이 CAGR 21.3%로 성장할 것으로 예측됩니다.
세계 오믹스 연구 분야 인공지능 시장 - 주요 동향 및 촉진요인 정리
오믹스 연구의 진화에 인공지능이 필수적인 이유는 무엇인가?
인공지능(AI)은 유전체학, 전사체학, 단백질체학, 대사체학, 후성유전체학을 포함한 오믹스 연구에서 기존의 바이오인포매틱스로는 너무 복잡하고 방대한 고차원 생물학적 데이터세트를 분석할 수 있게 함으로써 변화를 초래하는 존재가 되어가고 있습니다. 변화를 초래하는 존재가 되고 있습니다. 오믹스 기술은 대량의 다층 데이터를 생성하므로 의미 있는 생물학적 패턴, 질병 메커니즘, 치료 타겟을 밝히기 위해서는 통합적이고 역동적인 모델링 접근법이 필요한 경우가 많습니다. 상관관계 규명, 유전자와 질병의 연관성 예측, 단백질 구조 모델링, 바이오마커 발굴에 있으며, 기존 방법보다 훨씬 더 높은 정확도와 확장성을 가지고 있음이 입증되고 있습니다.
생명과학이 개인화된 시스템 수준의 의료로 전환됨에 따라 AI 기반 플랫폼은 숨겨진 패턴을 감지하고, 차원을 줄이고, 조기 진단, 약물 반응 프로파일링, 질병 진행 모니터링에 핵심적인 예측 모델을 생성함으로써 이를 촉진합니다. 약물 반응 프로파일링, 질병 진행 모니터링의 중심이 되는 예측 모델을 생성함으로써 이를 촉진합니다. 오믹스 연구와 AI의 융합은 생의학 연구자, 제약사, 정밀의학 플랫폼이 가설을 세우고, 발견을 가속화하고, 개인화된 치료 전략에 접근하는 방법을 재정의하고 있습니다.
AI 모델은 어떻게 멀티오믹스 통합과 예측 정확도를 높이는가?
오믹스 연구에서의 인공지능의 적용은 특히 유전체, 트랜스크립톰, 프로테옴, 메타볼롬의 각 계층에 걸친 데이터를 통합하여 전체 생물학적 모델을 구축하는 멀티오믹스 통합에 큰 변화를 가져오고 있습니다. 지원 벡터 머신(SVM), 랜덤 포레스트, 심층 신경망과 같은 머신러닝 알고리즘을 통해 연구자들은 분자 시그니처와 암 아형, 신경 퇴행성 질환, 희귀질환과 같은 복잡한 표현형과의 잠재적 연관성을 밝혀낼 수 있습니다. 멀티오믹스 분석의 공통적인 과제인 데이터 불균일성, 결측치, 비선형 관계 관리에 탁월합니다.
컨볼루션 신경망(CNN), 오토인코더와 같은 딥러닝 아키텍처는 유전자형과 표현형의 연결고리 매핑, 단백질 접힘 예측(구조생물학에서 알파폴드(AlphaFold)의 혁신 등), 신규 신약 타겟의 식별 등에 활용되고 있습니다. 자연 언어 처리(NLP) 툴은 비정형화된 생물학 문헌에서 지식을 추출하여 오믹스 주석과 가설을 보강하고 있습니다. 또한 비지도 학습은 사전 라벨링 없이 환자 계층화 및 질병 분류를 위해 오믹스 데이터를 클러스터링하는 데 도움을 주고 있습니다. 이러한 AI의 능력을 통해 연구자들은 설명적 분석에서 예측적 분석, 나아가 처방적 분석으로 전환하고, 새로운 데이터 입력에 따라 진화할 수 있는 동적 학습 기반 생물학 모델을 만들 수 있게 됩니다.
오믹스 연구에서의 인공지능은 어디에서 추진력을 얻고 있으며, 어떤 분야가 응용을 주도하고 있는가?
오믹스 연구, 학술연구, 제약 R&D, 정밀 종양학, 희귀질환 진단, 농업 생명공학 분야에서 인공지능의 적용이 가속화되고 있습니다. 북미가 시장을 주도하고 있으며, 주요 기관, 유전체학 스타트업, 바이오 제약사들이 바이오마커 탐색 가속화, 시험 설계 최적화, 동반 진단 약물 개발에 AI를 도입하고 있습니다. 유럽, 특히 독일, 영국, 북유럽 국가에서는 EU가 지원하는 연구 프레임워크를 통해 AI를 활용한 오믹스 공동연구가 빠르게 성장하고 있습니다. 한편, 중국, 일본, 한국을 중심으로 한 아시아태평양에서는 국가적 정밀의료 구상 및 집단 시퀀싱 프로젝트를 지원하기 위해 AI 유전체학 플랫폼에 대한 전략적 투자가 이루어지고 있습니다.
암 연구는 여전히 가장 활발한 분야로, AI 모델은 분자 아형에 따라 종양을 계층화하고, 치료 반응을 예측하고, 실시간 오믹스 데이터를 사용하여 내성 메커니즘을 모니터링하기 위해 적용되고 있습니다. 약물유전체학에서는 AI가 유전자형과 약물 반응 프로파일을 연결하여 약물 대사 연구를 안내하고 있습니다. 알츠하이머병, 파킨슨병과 같은 신경 퇴행성 질환도 AI 모델이 멀티오믹스 및 이미지 데이터를 분석하여 초기 바이오마커와 진행 패턴을 밝혀내고 있습니다. 농업 분야에서는 AI를 활용한 오믹스를 통해 기후 변화에 강한 작물 개발, 형질 선택, 병원균 내성 최적화가 가능해지고 있습니다. 이러한 폭넓은 적용 범위는 학제간 공동연구를 촉진하고 새로운 상업화의 길을 만들어내고 있습니다.
오믹스 연구용 인공지능의 세계 성장 원동력은?
오믹스 연구에서의 인공지능의 성장은 여러 가지 요인에 의해 이루어지고 있는데, 그 중 가장 큰 요인은 하이스루풋 시퀀싱 기술의 폭발적인 보급, 멀티오믹스 플랫폼의 저렴한 가격, 맞춤형 의료에서 통합적 분석의 중요성 등입니다. 주요 원동력은 대규모 코호트 연구, 임상시험 및 집단 전체 유전체 구상 등을 통한 오믹스 데이터 생성의 급격한 증가이며, AI는 이러한 데이터세트에서 가치를 창출하고 진단, 치료 및 예방 의료를 위한 실용적인 인사이트으로 전환하는 데 필요한 컴퓨팅 인프라를 제공합니다.
NIH의 All of Us Research Program, UK Biobank, China Precision Medicine initiative와 같은 구상은 유전체 해석 및 리스크 모델링에 AI를 도입하고 있습니다. 및 리스크 모델링을 위해 AI를 도입하고 있습니다. 클라우드 기반 바이오인포매틱스 플랫폼과 AI-as-a-service 모델은 연구기관과 중견 바이오기업의 도입 장벽을 더욱 낮추고 있습니다. 데이터 공유 프레임워크의 강화는 데이터 익명화 및 협업 학습의 발전과 함께 모델의 견고성을 극대화하면서 프라이버시 문제를 해결하는 데 도움이 되고 있으며, AI가 생물의학 연구를 재구성하는 과정에서 중요한 질문이 제기되고 있습니다. 인공지능이 확장 가능하고, 윤리적이고, 임상적으로 실행 가능한 오믹스를 주류 의료 및 집단 수준의 질병 예방에 통합할 수 있는가?
부문
제공(소프트웨어, 서비스), 테크놀러지(시퀀스, 에피게노믹스, 단백질체학, 대사체학, 기타 테크놀러지), 애플리케이션(종양학, 감염증, 신경학, 심혈관질환, 면역학, 기타 애플리케이션), 최종사용자(학술·연구기관, 바이오 제약회사, 기타 최종사용자)
조사 대상 기업의 예(주목 32사)
Agilent Technologies
Amazon Web Services
Anima Biotech
Antiverse
Atomwise
BenevolentAI
BGI Genomics
Bio-Rad Laboratories
Bruker Corporation
Caris Life Sciences
Danaher Corporation
Deep Genomics
Exscientia
Fabric Genomics
GE Healthcare
GeneDx
Genetic Leap
Healx
Illumina Inc.
Insilico Medicine
관세 영향 계수
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월: 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월: 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석 :
미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국
업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황에서 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 최고 이코노미스트를 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
KSA
영문 목차
영문목차
Global Artificial Intelligence in Omics Studies Market to Reach US$4.5 Billion by 2030
The global market for Artificial Intelligence in Omics Studies estimated at US$913.5 Million in the year 2024, is expected to reach US$4.5 Billion by 2030, growing at a CAGR of 30.4% over the analysis period 2024-2030. AI Software, one of the segments analyzed in the report, is expected to record a 27.7% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the AI Services segment is estimated at 35.3% CAGR over the analysis period.
The U.S. Market is Estimated at US$240.1 Million While China is Forecast to Grow at 28.9% CAGR
The Artificial Intelligence in Omics Studies market in the U.S. is estimated at US$240.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$679.7 Million by the year 2030 trailing a CAGR of 28.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.3% and 26.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 21.3% CAGR.
Global Artificial Intelligence in Omics Studies Market - Key Trends & Drivers Summarized
Why Is Artificial Intelligence Becoming Indispensable in the Evolution of Omics Research?
Artificial Intelligence (AI) is becoming a transformative force in omics studies-including genomics, transcriptomics, proteomics, metabolomics, and epigenomics-by enabling the analysis of vast, high-dimensional biological datasets that would otherwise be too complex and voluminous for traditional bioinformatics. Omics technologies generate massive quantities of multi-layered data, often requiring integrative and dynamic modeling approaches to uncover meaningful biological patterns, disease mechanisms, and therapeutic targets. AI, particularly machine learning (ML) and deep learning algorithms, is proving instrumental in identifying correlations, predicting gene-disease associations, modeling protein structures, and discovering biomarkers with far greater precision and scalability than conventional methods.
As life sciences shift toward personalized, systems-level medicine, the need for computational tools that can synthesize cross-omics data into actionable insights is becoming increasingly urgent. AI-driven platforms facilitate this by detecting hidden patterns, reducing dimensionality, and generating predictive models that are central to early diagnosis, drug response profiling, and disease progression monitoring. The convergence of omics research and AI is redefining how biomedical researchers, pharmaceutical companies, and precision medicine platforms develop hypotheses, accelerate discovery, and move closer to individualized treatment strategies.
How Are AI Models Enhancing Multi-Omics Integration and Predictive Accuracy?
The application of AI in omics is particularly transformative in multi-omics integration-combining data across genomic, transcriptomic, proteomic, and metabolomic layers to build holistic biological models. Machine learning algorithms, including support vector machines (SVMs), random forests, and deep neural networks, are enabling researchers to uncover latent associations between molecular signatures and complex phenotypes, such as cancer subtypes, neurodegenerative conditions, or rare diseases. AI models excel at managing data heterogeneity, missing values, and non-linear relationships-common challenges in multi-omics analytics.
Deep learning architectures, including convolutional neural networks (CNNs) and autoencoders, are being used to map genotype-to-phenotype links, predict protein folding (e.g., AlphaFold’s breakthrough in structural biology), and identify novel drug targets. Natural language processing (NLP) tools are extracting knowledge from unstructured biological literature to enrich omics annotations and hypotheses. Moreover, unsupervised learning is helping in clustering omics data for patient stratification and disease classification without prior labeling. These AI capabilities are empowering researchers to move from descriptive to predictive and even prescriptive analytics-creating dynamic, learning-based models of biology that can evolve with new data inputs.
Where Is AI in Omics Gaining Momentum and Which Fields Are Leading Applications?
AI applications in omics are gaining momentum in academic research, pharmaceutical R&D, precision oncology, rare disease diagnostics, and agricultural biotechnology. North America dominates the market, with leading institutions, genomics startups, and biopharma companies deploying AI to accelerate biomarker discovery, optimize trial designs, and develop companion diagnostics. Europe, particularly Germany, the U.K., and the Nordic countries, is seeing robust growth in AI-driven omics collaborations through EU-funded research frameworks. Meanwhile, Asia-Pacific-driven by China, Japan, and South Korea-is making strategic investments in AI genomics platforms to support national precision medicine initiatives and population-scale sequencing projects.
Cancer research remains the most active area, with AI models being applied to stratify tumors based on molecular subtypes, predict therapy response, and monitor resistance mechanisms using real-time omics data. In pharmacogenomics, AI is guiding drug metabolism studies by linking genotypes with drug response profiles. Neurodegenerative diseases such as Alzheimer’s and Parkinson’s are also gaining attention, where AI models analyze multi-omics and imaging data to uncover early biomarkers and progression patterns. In the agricultural space, AI-powered omics is enabling the development of climate-resilient crops, trait selection, and pathogen resistance optimization. This broad scope of application is catalyzing interdisciplinary collaborations and creating new commercialization pathways.
What Is Driving the Global Growth of Artificial Intelligence in Omics Studies?
The growth in artificial intelligence in omics studies is driven by several factors, including the explosion of high-throughput sequencing technologies, the affordability of multi-omics platforms, and the critical need for integrative analytics in personalized medicine. A key driver is the exponential increase in omics data generation from large-scale cohort studies, clinical trials, and population-wide genome initiatives. AI provides the computational infrastructure necessary to extract value from these datasets-turning them into actionable insights for diagnostics, therapeutics, and preventive healthcare.
Supportive policies and investments from governments, health systems, and private stakeholders are also fueling market expansion. Initiatives like the NIH’s All of Us Research Program, UK Biobank, and the China Precision Medicine initiative are deploying AI for genomic interpretation and risk modeling. Cloud-based bioinformatics platforms and AI-as-a-service models are further lowering barriers for adoption by research institutions and mid-sized biotech firms. Enhanced data sharing frameworks, coupled with advances in data anonymization and federated learning, are helping address privacy concerns while maximizing model robustness. As AI continues to reshape biomedical research, a critical question emerges: Can artificial intelligence enable a scalable, ethical, and clinically actionable integration of omics into mainstream healthcare and population-level disease prevention?
SCOPE OF STUDY:
The report analyzes the Artificial Intelligence in Omics Studies market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Offering (Software, Services); Technology (Sequencing, Epigenomics, Proteomics, Metabolomics, Other Technologies); Application (Oncology, Infectious Diseases, Neurology, Cardiovascular Diseases, Immunology, Other Applications); End-User (Academic & Research Institutes, Biopharmaceutical Company, Other End-Users)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.
Select Competitors (Total 32 Featured) -
Agilent Technologies
Amazon Web Services
Anima Biotech
Antiverse
Atomwise
BenevolentAI
BGI Genomics
Bio-Rad Laboratories
Bruker Corporation
Caris Life Sciences
Danaher Corporation
Deep Genomics
Exscientia
Fabric Genomics
GE Healthcare
GeneDx
Genetic Leap
Healx
Illumina Inc.
Insilico Medicine
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Artificial Intelligence in Omics Studies - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
AI Algorithms Unlock New Biological Insights Across Genomics, Transcriptomics, and Proteomics
Machine Learning Accelerates Target Discovery in Complex Multi-Omics Datasets
AI-Powered Pattern Recognition Enables Early Disease Biomarker Identification in Omics Studies
Integration of AI with Next-Generation Sequencing Platforms Enhances Data Interpretation Speed
Personalized Medicine Strategies Leverage AI to Decode Omics Complexity in Clinical Contexts
Multi-Omics Data Fusion Using AI Enhances Predictive Modeling of Disease Progression
AI Platforms Support Scalable Annotation and Classification of Large Omics Repositories
Deep Learning Models Identify Non-Obvious Biological Relationships Within Omics Networks
Regulatory Interest in Explainable AI Tools Strengthens Clinical Use of Omics-Based Diagnostics
AI Automation in Omics Pipelines Reduces Time-to-Insight for Drug and Biomarker Discovery
Pharma and Biotech R&D Pipelines Embrace AI in Omics to Cut Costs and Improve Yield
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Artificial Intelligence in Omics Studies Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Artificial Intelligence in Omics Studies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Immunology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Immunology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 19: World 6-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Biopharmaceutical Company by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 23: World 6-Year Perspective for Biopharmaceutical Company by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 25: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Sequencing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World 6-Year Perspective for Sequencing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 28: World Recent Past, Current & Future Analysis for Epigenomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 29: World 6-Year Perspective for Epigenomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 30: World Recent Past, Current & Future Analysis for Proteomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 31: World 6-Year Perspective for Proteomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Metabolomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World 6-Year Perspective for Metabolomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 34: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 35: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 36: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 37: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 38: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 39: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 40: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 41: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
CANADA
TABLE 44: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 46: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 47: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 48: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 49: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 50: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
JAPAN
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 52: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 53: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 54: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 55: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 56: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 58: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 59: Japan 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
CHINA
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 60: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 61: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 62: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 64: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 65: China 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 66: China Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 67: China 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
EUROPE
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 68: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 69: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 70: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 71: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 72: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 73: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 74: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 76: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 77: Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
FRANCE
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 78: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 79: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 80: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 82: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 83: France 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 84: France Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 85: France 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
GERMANY
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 86: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 88: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 89: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 90: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 91: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 92: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 93: Germany 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
ITALY
TABLE 94: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 95: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 96: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 97: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 98: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 100: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 101: Italy 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
UNITED KINGDOM
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 102: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 103: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 104: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 106: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 107: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 108: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 109: UK 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
REST OF EUROPE
TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 113: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 114: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 115: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 116: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: Rest of Europe 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
ASIA-PACIFIC
Artificial Intelligence in Omics Studies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 119: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 121: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 124: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 125: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
REST OF WORLD
TABLE 126: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Offering - Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 127: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Offering - Percentage Breakdown of Value Sales for Software and Services for the Years 2025 & 2030
TABLE 128: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Application - Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Application - Percentage Breakdown of Value Sales for Neurology, Cardiovascular Diseases, Immunology, Other Applications, Oncology and Infectious Diseases for the Years 2025 & 2030
TABLE 130: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by End-user - Academic & Research Institutes, Biopharmaceutical Company and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 131: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by End-user - Percentage Breakdown of Value Sales for Academic & Research Institutes, Biopharmaceutical Company and Other End-Users for the Years 2025 & 2030
TABLE 132: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Omics Studies by Technology - Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 133: Rest of World 6-Year Perspective for Artificial Intelligence in Omics Studies by Technology - Percentage Breakdown of Value Sales for Sequencing, Epigenomics, Proteomics, Metabolomics and Other Technologies for the Years 2025 & 2030
